What does series A readiness look like in healthtech?

Series A readiness in healthtech centres on three convergent signals: proven technology, early revenue, and a clear scaling inflection point.

Traction is the headline. Early founders talk about product-market fit and initial revenue [#222], but investors drilling deeper look for something more specific: technology that works clinically, adoption that's validated, and evidence you can expand into new markets or use cases [#404]. This means your product isn't theoretical anymore. It's in market, generating revenue, and demonstrating that clinicians or patients will actually use it.

The harder signal is execution readiness. You need to show you can move fast on the next phase. One founder raised a $16 million Series A, then immediately began preparing a top-up specifically because an FDA clearance pathway opened earlier than expected [#359]. That's the posture investors want: not just hitting a funding milestone, but knowing what you're solving for next and having the operational clarity to move toward it.

Series A failure rates are notably high in healthtech [#111], often because founders raise before they've genuinely proven adoption or haven't thought through regulatory/reimbursement requirements. The founders who succeed tend to be over-prepared on these specifics, not under-prepared. They're not hoping investors will tell them what readiness looks like.